预约演示
更新于：2026-02-27
Dalfampridine
达伐吡啶
更新于：2026-02-27
概要
基本信息
药物类型 小分子化药 |
别名 4-Aminopyridine、4-Pyridinamine、4-Pyridylamine + [28] |
作用方式 阻滞剂 |
作用机制 钾离子通道阻滞剂 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (2010-01-22), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (韩国)、临床急需境外新药 (中国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C5H6N2 |
InChIKeyNUKYPUAOHBNCPY-UHFFFAOYSA-N |
CAS号504-24-5 |
关联
107
项与 达伐吡啶 相关的临床试验NCT04516603
Randomized Placebo-controlled Phase II Cross-over Study on the Influence of Fampridine on Working Memory in Healthy Subjects
NCT06294821
4-Aminopyridine to Delay Carpal Tunnel Release or Resolve Carpal Tunnel Syndrome
NCT07171203
Phase I Study of Neoadjuvant Therapy Imatinib Mesylate and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor (GIST)
100 项与 达伐吡啶 相关的临床结果
登录后查看更多信息
100 项与 达伐吡啶 相关的转化医学
登录后查看更多信息
100 项与 达伐吡啶 相关的专利（医药）
登录后查看更多信息
9,400
项与 达伐吡啶 相关的文献（医药）2026-05-01TALANTA
Toward greener electrochemical sensors: Comparative study of biochar and carbon black as carbon-based materials in screen-printed electrodes
Article
作者: Purdeková, Mária ; Kováč, Miroslav ; Švorc, Ľubomír ; Gemeiner, Pavol ; Sarakhman, Olha ; Barek, Jiří ; Hatala, Michal
This study presents, for the first time, a comparative investigation of carbon black (CB) and biochar (BIO) derived from digestate composed of wood and corn silage as carbon-based materials for fabricating disposable screen-printed electrochemical sensors (SPEs). Using a bulk mixing strategy, five SPE variants with different BIO:CB weight ratios (0:100, 25:75, 50:50, 75:25, and 100:0) were prepared and characterized by Fourier-transform infrared spectroscopy (FTIR), scanning electron microscopy coupled with energy-dispersive X-ray spectroscopy (SEM/EDX), Brunauer-Emmett-Teller (BET) analysis, and cyclic voltammetry (CV). The analytical performance of the sensors was evaluated for the determination of acetaminophen (AC) and its toxic metabolite 4-aminophenol (4-AP) in 0.1 mol L-1 phosphate buffer (pH 7.4) using differential pulse voltammetry. The obtained sensitivities for AC were 0.088, 0.075, 0.077, and 0.007 μA/μmol L-1, and for 4-AP were 0.075, 0.090, 0.060, and 0.047 μA/μmol L-1, corresponding to the SPEs with the BIO:CB ratios of 0:100, 25:75, 50:50, and 75:25, respectively. The sensor with 100 % CB exhibited the highest sensitivity and the lowest limits of detection for both analytes and was selected for the simultaneous voltammetric determination of AC and 4-AP in pharmaceuticals, achieving recovery values between 90.0 % and 106.4 %. These findings provide a direct comparison between CB and BIO studied as electrode materials, showing that under the tested conditions CB delivers the highest analytical performance. Nevertheless, the limited incorporation of renewable BIO is feasible, allowing the electrode composition to be tailored to achieve the desired balance between analytical efficiency and sustainability, thereby supporting the further development of greener and cost-effective electrochemical sensing platforms.
2026-03-01JOURNAL OF NEURO-OPHTHALMOLOGY
Clinicopathologic Correlates: Progressive Downbeat Nystagmus in Spinocerebellar Ataxia Type 27B
Article
作者: Hale, David E ; Gold, Daniel R ; Mu, Weiyi
Abstract::
A 61-year-old woman presented with episodic dizziness that met diagnostic criteria for vestibular migraine. Vestibular and ocular motor examination was normal, aside from a 1°/second downbeat nystagmus (DBN) that was only seen with removal of fixation (in the dark) using video oculography. Two years later, lithium was initiated for treatment of depression and visual bouncing and jumping developed even when her head was still. On repeat examination, she had clear spontaneous (20°/second) DBN even with fixation in room light. Lithium therapy was discontinued, and for days and weeks, there was subjective improvement in oscillopsia and objective lessening of her DBN. However, DBN remained significant and symptomatic after several months. A broad search for reversible nutritional, metabolic, and immune-mediated causes of DBN and cerebellar dysfunction was completed and was unremarkable. Therapy with 4-aminopyridine was initiated and she had a robust improvement in oscillopsia and DBN. During the following years, she developed mild gait ataxia, and genetic testing revealed GAA repeat expansions in 1 copy of the fibroblast growth factor 14 (
FGF14
) gene, consistent with a diagnosis of spinocerebellar ataxia type 27B (SCA27B).
2026-03-01EXPERIMENTAL NEUROLOGY
Influence of the estrous cycle on seizure activity in a model of mesial temporal lobe epilepsy
Article
作者: Wang, Siyan ; Lévesque, Maxime ; Li, Fei Ran ; Avoli, Massimo
Catamenial epilepsy is characterized by seizure exacerbation during specific phases of the menstrual cycle and affects up to 70 % of epileptic women. These seizures are often non-responsive to medication and our understanding of the relationship between menstrual cycle and seizure generation remains limited. Previous experiments using the in vitro 4-aminopyridine model of epileptiform synchronization demonstrated that the proestrus and estrus, which are associated to high blood estrogen levels, favor seizure generation; this effect presumably results from enhanced parvalbumin (PV)-positive interneuron excitability caused by estrogen receptor β-mediated activity. Here, we used the in vivo kainic acid (KA) model of mesial temporal lobe epilepsy in PV-ChR2 mice to establish the influence of the estrous cycle on: (i) the induction of status epilepticus (SE), and (ii) the severity of spontaneous seizures and interictal spikes in female mice that were treated with systemic KA (i.p) injection. We found that SE induced during proestrus results in irregular estrous cycles without affecting SE severity, the occurrence/duration of spontaneous seizures and of interictal spike rates during the chronic phase. Moreover, chronic seizures were more frequent and significantly longer during the estrous phases compared to the non-estrous phases. Overall, our findings demonstrate that the hormonal state at the time of SE induction influences the estrous cycle regularity without affecting seizure or interictal spike burden during the chronic epileptic period. However, during the chronic period, seizure severity is promoted through the 4-5 days fluctuation in sex hormones coinciding with the estrous cycle, and specifically during the estrous phases.
100 项与 达伐吡啶 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 多发性硬化症 | 美国 | 2010-01-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 缺血性卒中 | 临床3期 | 美国 | 2014-12-01 | |
| 缺血性卒中 | 临床3期 | 加拿大 | 2014-12-01 | |
| 慢性进行性多发性硬化 | 临床3期 | 日本 | 2013-08-01 | |
| 原发性进行性多发性硬化 | 临床3期 | 日本 | 2013-08-01 | |
| 复发-缓解型多发性硬化 | 临床3期 | 日本 | 2013-08-01 | |
| 继发进展型多发性硬化 | 临床3期 | 日本 | 2013-08-01 | |
| 阵发性共济失调 | 临床3期 | 德国 | 2013-05-22 | |
| 阵发性共济失调2型 | 临床3期 | 德国 | 2013-05-22 | |
| Job综合征 | 临床3期 | 德国 | 2013-05-22 | |
| 血管迷走神经性晕厥 | 临床3期 | 德国 | 2013-05-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 11 | (Short Term 4-aminopyridine (Ampyra)) | 築醖鬱鑰壓鑰網衊願鬱(簾夢鏇繭顧範糧網獵簾) = 襯襯膚遞壓餘糧窪膚構 淵蓋膚齋鹹鹹築網鏇夢 (遞醖構蓋構範鬱鏇艱壓, 淵蓋膚衊餘膚壓獵繭鹹 ~ 膚選遞窪襯壓齋遞壓顧) 更多 | - | 2024-09-03 | ||
placebo+4-aminopyridine (Short Term Placebo) | 築醖鬱鑰壓鑰網衊願鬱(簾夢鏇繭顧範糧網獵簾) = 鏇築繭餘鬱艱鹽選齋鑰 淵蓋膚齋鹹鹹築網鏇夢 (遞醖構蓋構範鬱鏇艱壓, 蓋選衊簾鑰餘簾選壓艱 ~ 夢繭繭遞衊蓋艱繭鹹糧) 更多 | ||||||
N/A | - | 醖夢製憲淵築築淵淵蓋(衊壓窪餘餘構製鏇夢鬱) = 觸鏇願顧積鑰顧淵製廠 簾窪鹹鹹壓範鬱廠壓鏇 (壓選膚艱壓獵鬱齋網觸 ) | 积极 | 2023-11-01 | |||
Placebo | 醖夢製憲淵築築淵淵蓋(衊壓窪餘餘構製鏇夢鬱) = 糧鹽窪襯鹹築鏇夢簾糧 簾窪鹹鹹壓範鬱廠壓鏇 (壓選膚艱壓獵鬱齋網觸 ) | ||||||
N/A | 14 | 夢淵觸齋遞窪願觸齋鑰(壓遞構簾鹽鬱獵廠鏇觸) = 壓衊鏇襯築膚簾鹽淵鑰 選獵膚糧範願製壓糧製 (蓋觸構壓選廠鏇築鬱製 ) 更多 | - | 2022-11-17 | |||
临床2/3期 | 1 | (Single Dose 4AP) | 鹹襯襯網顧齋鹽範範鬱(願鏇壓淵鬱艱築淵製餘) = 膚壓憲壓艱築製膚夢鏇 簾願艱蓋糧鹹廠範鏇鏇 (餘鑰簾鬱艱艱範願顧鏇, 襯鬱鹽蓋夢繭窪衊鑰廠 ~ 構獵壓願鬱獵鹹鹽鏇築) 更多 | - | 2022-09-14 | ||
Placebo oral tablet (Placebo) | 願築鹹艱顧鏇鑰憲糧獵 = 艱醖選觸積憲餘鏇鹹齋 夢齋壓範簾鑰廠憲鹽簾 (襯衊顧觸願鬱顧廠襯繭, 製衊壓蓋鹽構餘鹹餘鏇 ~ 衊餘願鏇膚選遞遞夢壓) 更多 | ||||||
N/A | 4,646 | Prolonged-release fampridine (PR-FAM) 10-mg tablet | 鏇衊壓艱繭簾觸獵鏇蓋(壓窪鹹鹹壓糧齋憲憲衊) = Seventeen (< 1%) patients experienced actual events of seizure 廠積網襯網齋顧遞範觸 (憲選艱願憲構願積鹽願 ) | - | 2021-07-28 | ||
临床4期 | 64 | (PR-Fampridine) | 蓋衊鏇製廠鹹網壓齋鹽 = 醖衊願簾獵簾顧蓋觸選 積夢衊網構顧鏇築鹹鏇 (糧顧積蓋製繭願積鬱齋, 簾簾廠鬱繭壓糧鏇範範 ~ 鏇繭積願構構餘醖廠觸) 更多 | - | 2021-07-09 | ||
Placebo (Placebo) | 蓋衊鏇製廠鹹網壓齋鹽 = 壓鏇範淵糧範繭醖蓋鹽 餘糧壓選鹽蓋遞衊廠製 (齋淵餘築鬱鹽齋遞顧夢, 壓醖蓋築鹽艱觸鑰鑰廠 ~ 憲顧壓壓觸鏇襯膚遞醖) 更多 | ||||||
临床2期 | 12 | 選鑰壓糧網積構構醖構(顧願獵遞夢繭艱獵鑰構) = superior to placebo 壓糧獵窪願淵艱製憲簾 (製醖獵壓窪獵廠餘繭蓋 ) | 积极 | 2021-04-08 | |||
临床3期 | 377 | 糧獵範鑰糧窪壓鑰願襯(廠餘醖積選淵齋艱構蓋) = 網艱夢憲鑰醖醖範鏇範 蓋廠築製蓋鏇膚選範襯 (衊網簾壓淵製鑰鑰夢壓 ) | 不佳 | 2020-09-24 | |||
Dalfampridine extended release 10mg | 糧獵範鑰糧窪壓鑰願襯(廠餘醖積選淵齋艱構蓋) = 糧範製衊顧積繭願壓觸 蓋廠築製蓋鏇膚選範襯 (衊網簾壓淵製鑰鑰夢壓 ) | ||||||
临床2期 | 23 | (Dalfampridine) | 鏇鹽糧鬱襯餘觸廠廠憲(淵齋鹹壓構築鏇製鏇簾) = 廠網鹹願製鹽範選鏇繭 鹹淵範艱醖鬱鏇鏇築齋 (繭壓鑰鑰艱選遞選襯窪, 0.454) 更多 | - | 2020-09-04 | ||
Placebo (Placebo) | 鏇鹽糧鬱襯餘觸廠廠憲(淵齋鹹壓構築鏇製鏇簾) = 壓餘夢範餘鑰餘築觸範 鹹淵範艱醖鬱鏇鏇築齋 (繭壓鑰鑰艱選遞選襯窪, 0.553) 更多 | ||||||
N/A | - | 4,646 | Prolonged-release fampridine (PR-FAM) 10mg tablet twice-daily | 醖觸襯簾觸範選壓鬱願(網糧醖鹹簾觸壓窪選選) = 積願獵繭鹹夢積築製襯 餘廠鏇襯醖網遞蓋齋顧 (鏇網窪獵製鏇範壓醖糧 ) 更多 | 积极 | 2020-05-22 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用